AMAM

Ambrx Biopharma, Inc. Common Stock

Delisted

AMAM was delisted on the 6th of March, 2024.

16 hedge funds and large institutions have $152M invested in Ambrx Biopharma, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.25%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
4
Reduced
5
Closed
1
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
Fidelity Investments
1
Fidelity Investments
Massachusetts
$34.8M 3,855,025 -1,200 -0%
BlackRock
2
BlackRock
New York
$25.9M 2,869,486 +2,049,265 +250%
CAM
3
Cormorant Asset Management
Massachusetts
$22.5M 2,486,386
AG
4
Artal Group
Luxembourg
$19.4M 2,152,291 +1,302,291 +153%
FI
5
Fosun International
China
$17.5M 1,932,591
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$17.4M 1,923,700 +96,408 +5%
SCM
7
Suvretta Capital Management
New York
$9.55M 1,057,735 +1,057,735 New
OCA
8
Octagon Capital Advisors
New York
$3.04M 336,868 -13,132 -4%
Millennium Management
9
Millennium Management
New York
$889K 98,419 -43,012 -30%
Norges Bank
10
Norges Bank
Norway
$632K 70,000
Tudor Investment Corp
11
Tudor Investment Corp
Connecticut
$182K 20,143
CCM
12
CAAS Capital Management
New York
$118K 13,068 -26,932 -67%
Renaissance Technologies
13
Renaissance Technologies
New York
$107K 11,800 +11,800 New
Morgan Stanley
14
Morgan Stanley
New York
$25K 2,800
MIFH
15
Migdal Insurance & Financial Holdings
Israel
$1K 124 -76 -38%
Bank of America
16
Bank of America
North Carolina
$1K 131 +30 +30%
GCM
17
Ghisallo Capital Management
Massachusetts
-15,000 Closed
CFGS
18
Concourse Financial Group Securities
Alabama